Korn Ferry Expected to Announce Strong Q3 Earnings; Analysts Adjust Price Targets

Natalie Pace

Financial wellness advocate and author focusing on eco-investing and protecting one's finances.

Korn Ferry (KFY), a prominent consulting firm, is poised to reveal its third-quarter financial outcomes before the market opens on Monday, March 9. Market watchers are optimistic, projecting a rise in the company's earnings per share to $1.24, an improvement from $1.19 in the same period last year. Revenue forecasts are also positive, with an anticipated $695.12 million, surpassing the previous year's $668.73 million, as reported by financial intelligence platforms.

Adding to the positive sentiment, Korn Ferry recently declared an increase in its quarterly dividend, raising it from 48 cents to 55 cents per share on March 5. This move, coupled with a 3% surge in share price to $65.08, reflects investor confidence. Esteemed analysts have been closely monitoring the company, with some adjusting their ratings and price targets. For instance, an analyst from Goldman Sachs maintained a 'Buy' rating but revised the price target to $74, while a Truist Securities analyst upheld a 'Buy' rating and elevated the target to $88. Conversely, a UBS analyst kept a 'Neutral' rating, increasing the price target to $72.

These adjustments in analyst forecasts underscore the dynamic nature of market expectations and the importance of professional insights in navigating investment decisions. The impending earnings report will provide crucial clarity on Korn Ferry's performance and future trajectory, influencing both current shareholders and potential investors.

Korn Ferry's consistent performance and strategic financial decisions, such as increasing dividends, demonstrate a commitment to shareholder value and a robust business model. These positive indicators, combined with diligent analyst evaluations, paint a picture of a company striving for growth and stability in a competitive market.

you may like

youmaylikeicon
BioXcel Therapeutics Stock Declines Despite Positive Opioid Withdrawal Drug Trial Results

BioXcel Therapeutics Stock Declines Despite Positive Opioid Withdrawal Drug Trial Results

By Bola Sokunbi
Technology and Biotech Lead as US Stocks Show Mixed Performance

Technology and Biotech Lead as US Stocks Show Mixed Performance

By Ramit Sethi
Unlocking Wealth: Warren Buffett's Dividend Strategy for Financial Growth

Unlocking Wealth: Warren Buffett's Dividend Strategy for Financial Growth

By Bola Sokunbi
Greencoat UK Wind's Resilience Amidst Sector Headwinds

Greencoat UK Wind's Resilience Amidst Sector Headwinds

By Bola Sokunbi
BigCommerce Strategic Shift: AI, Monetization, and Platform Evolution

BigCommerce Strategic Shift: AI, Monetization, and Platform Evolution

By Vicki Robin
Amending Your Tax Return: A Comprehensive Guide to Form 1040-X

Amending Your Tax Return: A Comprehensive Guide to Form 1040-X

By Mr. Money Mustache
South Bow Reports Robust Q4 and Full-Year 2025 Financial Results and Operational Milestones

South Bow Reports Robust Q4 and Full-Year 2025 Financial Results and Operational Milestones

By T. Harv Eker
RBC Capital Adjusts Price Target for Viridian Therapeutics to $42, Maintains Outperform Rating

RBC Capital Adjusts Price Target for Viridian Therapeutics to $42, Maintains Outperform Rating

By Dave Ramsey
Truist Elevates Price Target and Maintains Buy Rating for BridgeBio Pharma (BBIO)

Truist Elevates Price Target and Maintains Buy Rating for BridgeBio Pharma (BBIO)

By Dave Ramsey
Analysts Revise Forecasts for Guidewire Software After Strong Q2 Performance

Analysts Revise Forecasts for Guidewire Software After Strong Q2 Performance

By Bola Sokunbi
WEX: A Robust Payments Company with Undervalued Potential

WEX: A Robust Payments Company with Undervalued Potential

By Dave Ramsey
Micron Technology Stock Performance and Market Outlook

Micron Technology Stock Performance and Market Outlook

By Bola Sokunbi
New Tariffs by Trump Administration Insufficient to Cover Revenue Shortfall

New Tariffs by Trump Administration Insufficient to Cover Revenue Shortfall

By Natalie Pace
Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly

Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly

By JL Collins
Top 3 Industrials Stocks Poised for March Surge

Top 3 Industrials Stocks Poised for March Surge

By Ramit Sethi